Premium
Effect of RG 12525, an oral leukotriene D4 antagonist, on the airway response to inhaled leukotriene D4 in subjects with mild asthma.
Author(s) -
Wahedna I,
Wisniewski AS,
Tattersfield AE
Publication year - 1991
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1991.tb03941.x
Subject(s) - leukotriene d4 , placebo , antagonist , bronchoconstriction , asthma , leukotriene , medicine , anesthesia , leukotriene e4 , alternative medicine , receptor , pathology
We have studied the effect of RG 12525, an oral leukotriene D4 (LTD4) antagonist, on LTD4‐induced bronchoconstriction in eight male subjects with mild asthma (baseline FEV1 greater than 80% predicted) in a double‐ blind, placebo‐controlled fashion. RG 12525 800 mg displaced the dose‐ response curve for LTD4 to the right. The mean (95% confidence intervals) difference in log PC20FEV1 following RG 12525 and placebo was 2.88 (1.61, 4.17) doubling doses of LTD4 (P less than 0.01), a 7.5 fold difference. We conclude that RG 12525 when administered orally is an effective LTD4 antagonist in subjects with mild asthma.